Binding molecules to the human OX40 receptor
The present disclosure provides isolated binding molecules that bind to the human OX40R, nucleic acid molecules encoding an amino acid sequence of the binding molecules, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of using the binding molecules or compositions.
1. A method of treating cancer in a mammal in need thereof, comprising administering to the mammal a therapeutically effective amount of a binding molecule that competes for binding to human OX40 R with an antibody that comprises:
(a) a heavy chain variable region comprising the amino acid sequence of SEQ ID No: 7; and
(b) a light chain variable region comprising amino acid sequence of SEQ ID No: 8.
2. The method according to claim 1 , wherein the cancer is selected from the group consisting of hepatocellular carcinoma, squamous cell carcinoma, head and neck cancer, renal cell carcinoma, melanoma, breast cancer, prostate cancer, colorectal cancer, lung cancer, and hematological cancer.
3. A method of enhancing an immune response in a mammal, comprising administering to the mammal a therapeutically effective amount of a binding molecule that competes for binding to human OX40 R with an antibody that comprises:
(a) a heavy chain variable region comprising the amino acid sequence of SEQ ID No: 7; and
(b) a light chain variable region comprising amino acid sequence of SEQ ID No: 8.
4. The method according to claim 1 , wherein the binding molecule is a human antibody.
5. A method of inhibiting growth of a tumor in a mammals, comprising administering to the mammal a binding molecule that competes for binding to human OX40 R with an antibody that comprises:
(a) a heavy chain variable region comprising the amino acid sequence of SEQ ID No: 7; and
(b) a light chain variable region comprising the amino acid sequence of SEQ ID No: 8, wherein the binding molecule is in an amount effective to inhibit the growth of the tumor.
6. The method of claim 1 , wherein the binding molecule comprises:
(a) a heavy chain CDR1 comprising an amino acid sequence of SEQ ID NO: 1; (b) a heavy chain CDR2 comprising an amino acid sequence of SEQ ID NO: 2; and (c) a heavy chain CDR3 comprising an amino acid sequence of SEQ ID NO: 3.
7. The method of claim 1 , wherein the binding molecule comprises:
(a) a heavy chain CDR1 comprising an amino acid sequence of SEQ ID NO: 1; (b) a heavy chain CDR2 comprising an amino acid sequence of SEQ ID NO: 2; (c) a heavy chain CDR3 comprising an amino acid sequence of SEQ ID NO: 3; (d) a light chain CDR 1 comprising an amino acid sequence of SEQ ID NO: 4; (e) a light chain CDR2 comprising an amino acid sequence of SEQ ID NO: 5; and (f) a light chain CDR3 comprising an amino acid sequence of SEQ ID NO: 6.
8. The method of claim 1 , wherein the binding molecule comprises:
(a) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 7; and (b) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 8.
9. The method of claim 1 , wherein the binding molecule (a) binds to human OX40 R with a KD of 1×10 −6 M or less; and (b) has agonist activity on human OX40 R.
10. The method of claim 1 , wherein the binding molecule is a human, chimeric or humanized antibody.
11. The method of claim 1 , wherein the binding molecule comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 9.
12. The method of claim 1 , wherein the binding molecule comprises a light chain comprising the amino acid sequence of SEQ ID NO: 10.
13. The method of claim 2 , wherein the binding molecule is an antibody comprising: (a) a heavy chain CDR1 comprising an amino acid sequence of SEQ ID NO: 1; (b) a heavy chain CDR2 comprising an amino acid sequence of SEQ ID NO: 2; (c) a heavy chain CDR3 comprising an amino acid sequence of SEQ ID NO: 3; (d) a light chain CDR1 comprising an amino acid sequence of SEQ ID NO: 4; (e) a light chain CDR2 comprising an amino acid sequence of SEQ ID NO: 5; and (f) a light chain CDR3 comprising an amino acid sequence of SEQ ID NO: 6.
14. The method of claim 2 , wherein the binding molecule is an antibody comprising: (a) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 7; and (b) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 8.
15. The method of claim 2 , wherein the binding molecule is an antibody comprising a heavy chain comprising the amino acid sequence of SEQ ID NO: 9.
16. The method of claim 2 , wherein the binding molecule is an antibody comprising a light chain comprising the amino acid sequence of SEQ ID NO: 10.
17. The method of claim 1 , wherein the method further comprises administering one or more additional treatments selected from a therapeutic agent and radiation therapy.
18. The method of claim 17 , wherein the therapeutic agent is a chemotherapeutic agent, an immunotherapeutic agent, or a hormone therapeutic agent.
19. A method of treating cancer in a mammal in need thereof, comprising administering to the mammal a therapeutically effective amount of a binding molecule that specifically binds to human OX40 R and comprises a heavy chain comprising the amino acid sequence of SEQ ID No: 21.
20. A method of treating cancer in a mammal in need thereof, comprising administering to the mammal a therapeutically effective amount of a binding molecule that specifically binds to human OX40 R and comprises a light chain comprising the amino acid sequence of SEQ ID No: 22.
21. A method of treating cancer in a mammal in need thereof, comprising administering to the mammal a therapeutically effective amount of a binding molecule that comprises:
(a) a heavy chain comprising the amino acid sequence of SEQ ID No: 21; and
(b) a light chain comprising the amino acid sequence of SEQ ID No: 22.
22. The method according to claim 21 , wherein the cancer is selected from the group consisting of hepatocellular carcinoma, squamous cell carcinoma, head and neck cancer, renal cell carcinoma, melanoma, breast cancer, prostate cancer, colorectal cancer, lung cancer, and hematological cancer.